National

Former Wockhardt executive banned from securities market for 6 months by SEBI for insider trading

The Securities and Exchange Board of India (Sebi) has imposed a six-month ban on Yatendra Kumar, a former executive of Wockhardt Ltd, from participating in the securities market. Kumar has also been ordered to disgorge losses of over Rs 14 lakh resulting from his violation of insider trading rules. Additionally, he is prohibited from buying, selling, or dealing in Wockhardt Ltd securities for a period of one year.

Following an investigation into trading activities in Wockhardt’s scrip between January 2012 and August 2013, Sebi found evidence of Kumar’s involvement in trading based on unpublished price-sensitive information (UPSI). Specifically, Kumar traded during a time when he possessed UPSI related to the issuance of Form 483 by the US Food and Drug Administration (USFDA) to Wockhardt’s manufacturing facility in Waluj, Maharashtra.

Yatendra Kumar has been penalized by Sebi for engaging in trades using price-sensitive information (PSI) related to the issuance of Form 483 by the US Food and Drug Administration (USFDA). Form 483 contains detailed observations regarding objectionable conditions found during facility inspections. The USFDA issued Form 483 to Wockhardt on March 22, 2013, which constituted PSI. Wockhardt publicly disclosed this information on April 15, 2013, through a press release on its website, making the period from March 22 to April 15, 2013, a period of unpublished price-sensitive information (UPSI).

During this UPSI period, Kumar sold 6,841 shares between March 22 and April 14, 2013, and divested 1,041 shares between April 15, 2013, and July 31, 2013. Kumar admitted in his response to Sebi that he became aware of the issuance of Form 483 on March 22, 2013.

By engaging in these trades, Kumar managed to avoid a loss of Rs 14.23 lakh, thereby violating insider trading rules. Consequently, Sebi has imposed several restrictions on Kumar.

In a separate case, Wockhardt and its three promoter entities, Habil Khorakiwala, Murtaza Khorakiwala, and Huzaifa Khorakiwala, settled with Sebi last month regarding the alleged non-disclosure of adverse observations made by the USFDA about the company’s Waluj facility to the stock exchanges in 2013.

Meera Verma

Recent Posts

Centre Opposes Ex-Judges Panel To Monitor Stubble Burning In SC

The Centre on Friday opposed a proposal in the Supreme Court to form a committee…

4 hours ago

“It’s A Celebration For Us”: Delhi HC Bar Association Felicitates CJI Sanjiv Khanna

The Delhi High Court Bar Association on Friday honored Chief Justice of India Justice Sanjiv…

5 hours ago

International Criminal Court Issues Arrest Warrant For Israeli PM Netanyahu

The International Criminal Court has recently issued arrest warrants for Israeli Prime Minister Benjamin Netanyahu,…

5 hours ago

Cal HC Stays Demolition Of Illegal Constructions In WB’s Mandarmoni

The Calcutta High Court on Friday granted an interim stay on the demolition of alleged…

6 hours ago

SC To Pass Order On Pleas To Efface Words ‘Secular’, ‘Socialist’ From Preamble

The Supreme Court on Friday announced that it would deliver its order on November 25…

6 hours ago

Air Pollution: SC Questions Delhi Govt On Truck Entry Amid GRAP-4 Restrictions

The Supreme Court raised concerns on Friday about the "drastic" consequences of the GRAP Stage…

6 hours ago